Table 1 Correlation between TDO2 expression and clinicopathologic features in renal cell carcinoma
From: Clinicopathologic features of TDO2 overexpression in renal cell carcinoma
| Â | TDO2 expression, n (%) | Â | |
|---|---|---|---|
| Â | High | Low | p valuea |
Age | |||
  ≤ 65 | 21 (51.22) | 20 (48.78) | 0.1453 |
  > 65 | 30 (66.67) | 15 (33.33) |  |
Sex | |||
 Female | 13 (54.17) | 11 (45.83) | 0.5464 |
 Male | 38 (61.29) | 24 (38.71) |  |
Histological classification | |||
 ccRCC | 38 (60.32) | 25 (39.68) | 0.7511 |
 Non-ccRCC | 13 (56.52) | 10 (43.48) |  |
T grade | |||
 T1 | 23 (44.23) | 29 (55.73) | 0.0004 |
 T2/3/4 | 28 (82.35) | 6 (17.65) |  |
N grade | |||
 N0 | 46 (57.50) | 34 (42.50) | 0.2141 |
 N1/2 | 5 (83.33) | 1 (16.77) |  |
M grade | |||
 M0 | 37 (53.62) | 32 (46.38) | 0.0308 |
 M1 | 14 (82.35) | 3 (17.65) |  |
Stage | |||
 Stage I | 22 (56.86) | 29 (43.14) | 0.0002 |
 Stage II/III/IV | 29 (82.86) | 6 (17.14) |  |
Histological grade | |||
 Grade 1/2 | 27 (46.55) | 31 (53.45) | 0.0005 |
 Grade 3/4 | 24 (85.71) | 4 (14.29) |  |